Regeneron Pharmaceuticals, Inc. Share Price & Technical Analysis
REGN · $638.9 (-0.58%)
Healthcare / Biotechnology
$638.9
-0.58%
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degenerat…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-9% return in May, -5% avg return in past 3 year May month.
-15% return in 2026, 5% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -4% | 7% | 0% | -9% | -9% | – | – | – | – | – | – | – | -15% |
| 25 | -7% | 4% | -10% | -5% | -17% | 7% | 4% | 0% | -3% | 14% | 19% | 0% | 6% |
| 24 | 8% | 2% | -1% | -8% | 10% | 7% | 3% | 12% | -11% | -20% | -11% | -5% | -13% |
| 23 | 5% | 1% | 8% | -2% | -8% | -2% | 4% | 11% | -1% | -6% | 5% | 6% | 21% |
| 22 | -3% | 2% | 13% | -6% | 1% | -12% | -1% | 0% | 19% | 6% | 0% | -5% | 16% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$75.52B
P/E ratio
17.58
52W high
$821.1
52W low
$476.5
Volume
9,95,023
Beta
0.30
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Regeneron Pharmaceuticals, Inc. share price today?
- Regeneron Pharmaceuticals, Inc. (REGN) last traded around $638.9 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does REGN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for REGN. Download the app for real-time alerts.
- How can I analyze Regeneron Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.